Dechra Brand Guidelines

Fusidic Acid Brochure front cover

Fusidic Acid Brochure inside spread

TIME TO CHANGE

In the light of increasing development of antibiotic resistance in human and veterinary practice there is growing pressure on the veterinary sector to use antimicrobials sparingly and responsibly. The aim is to reduce overall the amount of antibiotics used, restrict the use of critically important molecules as defined by the World Health organisation (WHO) and slow down the development of antimicrobial resistance to safeguard effective molecules for veterinary and human use.

Fusidic acid is a unique antimicrobialmolecule. Itbelongs to a classof itsown (the fusidanes) and no cross resistancebetween fusidic acid andother antibiotics in clinical use hasbeen identified.Available in a rangeof topical antibiotic treatments fromDechra, it can help support the vet in successfully combatingbacterial infections that are sensitive to fusidic acid.

FUSIDIC ACID. A SECRET WEAPON IN THE FIGHT AGAINST ANTIBIOTIC RESISTANCE.

u Active in thepresenceofpus 1 Due to its lipophilic nature fusidic acid shows highpenetration of skin and remains stable and active in thepresenceofpus

Fusidic acid

u Narrow spectrum A narrow-spectrum antibioticwhich is effective against Gram-positivebacteria such as Staphylococcus spp. and Streptococcus spp.

u High efficacy against Staphylococcuspseudintermedius 2 , themost commonpathogen in canine skindisease

u Effective againstMRSP 3 As there is no cross-resistancewithother antibiotics fusidic acid is also effective against methicilin resistant Staphylococci (MRSP)

u Bacterialgrowth inhibitor Fusidic acid is abacterialprotein synthesis inhibitor,which interruptsbacterialgrowth and replication

u First-line treatment Classified as a highly important, rather than critically important, antimicrobial in humanmedicinewhich allows its use as first line treatment in veterinarymedicine u Topical treatment Fusidic acid isonly licensed for topicaluse in veterinary medicine, allowingdrug concentrations achieved at the siteof infection tobe a lot higher thanwith systemic administration and concentrations commonly exceed Minimum InhibitoryConcentrations (MIC) reducing the likelihoodof resistancedevelopment 3 .

TIMETOCHANGE